LOXL2 expression is associated with invasiveness and negatively influences survival in breast cancer patients

Breast Cancer Research and Treatment

Volumn 141, Issue 1, 2013, Pages 89-99

  Ahn, Sung Gwe ^a   Dong, Seung Myung ^c   Oshima, Akira ^d   Kim, Woo Ho ^e   Lee, Hak Min ^a   Lee, Seung Ah ^f   Kwon, Seung Hyun ^b   Lee, Ji Hae ^c   Lee, Jae Myun ^b   Jeong, Joon ^a   Lee, Hy De ^a   Green, Jeffrey E ^g  

^a Yonsei University College of Medicine   (South Korea)

^b Yonsei University College of Medicine   (South Korea)

^c National Cancer Center   (South Korea)

^d CHA University   (South Korea)

^e Seoul National University   (South Korea)

^f Eulji University   (South Korea)

^g NATIONAL CANCER INSTITUTE   (United States)

Author keywords

Breast cancer; Invasiveness; LOXL2; Triple negative

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; LYSYL OXIDASE LIKE 2 PROTEIN; MATRIGEL; PROGESTERONE RECEPTOR; PROTEIN LYSINE 6 OXIDASE; UNCLASSIFIED DRUG;

ADULT; ARTICLE; BREAST CANCER; CANCER CELL CULTURE; CANCER PATIENT; CANCER PROGNOSIS; CANCER SURVIVAL; CANCER TISSUE; CELL INVASION; CELL MIGRATION; CELL STRAIN BT549; CELL STRAIN MDA MB 231; CONTROLLED STUDY; EPITHELIAL MESENCHYMAL TRANSITION; GENE SILENCING; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; MAJOR CLINICAL STUDY; METASTASIS FREE SURVIVAL; OVERALL SURVIVAL; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TRIPLE NEGATIVE BREAST CANCER; TUMOR INVASION; WESTERN BLOTTING; WOUND HEALING;

ADULT; AMINO ACID OXIDOREDUCTASES; BREAST NEOPLASMS; CARCINOMA; CARCINOMA IN SITU; CELL LINE, TUMOR; CELL MOVEMENT; COLLAGEN; DISEASE-FREE SURVIVAL; DRUG COMBINATIONS; EPITHELIAL-MESENCHYMAL TRANSITION; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IN SITU HYBRIDIZATION; KAPLAN-MEIER ESTIMATE; LAMININ; MIDDLE AGED; NEOADJUVANT THERAPY; NEOPLASM INVASIVENESS; NEOPLASM METASTASIS; NEOPLASM PROTEINS; NEOPLASMS, MULTIPLE PRIMARY; PHYLLODES TUMOR; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; PROTEOGLYCANS; RNA INTERFERENCE; RNA, SMALL INTERFERING; SURVIVAL ANALYSIS; TISSUE ARRAY ANALYSIS; TRIPLE NEGATIVE BREAST NEOPLASMS;

EID: 84884290893     PISSN: 01676806     EISSN: 15737217     Source Type: Journal    
DOI: 10.1007/s10549-013-2662-3     Document Type: Article

References (32)

1. Parkin DM, Bray F, Ferlay J, Pisani P (2005) Global cancer statistics, 2002. CA Cancer J Clin 55:74-108
2. Jemal A, Siegel R, Ward E, Murray T, Xu J, Thun MJ (2007) Cancer statistics, 2007. CA Cancer J Clin 57:43-66
3. Piccart-Gebhart MJ, Procter M, Leyland-Jones B, Goldhirsch A, Untch M, Smith I, Gianni L, Baselga J, Bell R, Jackisch C, Cameron D, Dowsett M, Barrios CH, Steger G, Huang CS, Andersson M, Inbar M, Lichinitser M, Lang I, Nitz U, Iwata H, Thomssen C, Lohrisch C, Suter TM, Ruschoff J, Suto T, Greatorex V, Ward C, Straehle C, McFadden E, Dolci MS, Gelber RD (2005) Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med 353:1659-1672. doi: 10.1056/NEJMoa052306
4. Fernandez Y, Cueva J, Palomo AG, Ramos M, de Juan A, Calvo L, Garcia-Mata J, Garcia-Teijido P, Pelaez I, Garcia-Estevez L (2010) Novel therapeutic approaches to the treatment of metastatic breast cancer. Cancer Treat Rev 36:33-42. doi: 10.1016/j.ctrv.2009.10.001
5. Asuncion L, Fogelgren B, Fong KS, Fong SF, Kim Y, Csiszar K (2001) A novel human lysyl oxidase-like gene (LOXL4) on chromosome 10q24 has an altered scavenger receptor cysteine rich domain. Matrix Biol 20:487-491
6. Jourdan-Le Saux C, Tomsche A, Ujfalusi A, Jia L, Csiszar K (2001) Central nervous system, uterus, heart, and leukocyte expression of the LOXL3 gene, encoding a novel lysyl oxidase-like protein. Genomics 74:211-218
7. Kim Y, Boyd CD, Csiszar K (1995) A new gene with sequence and structural similarity to the gene encoding human lysyl oxidase. J Biol Chem 270:7176-7182
8. Saito H, Papaconstantinou J, Sato H, Goldstein S (1997) Regulation of a novel gene encoding a lysyl oxidase-related protein in cellular adhesion and senescence. J Biol Chem 272:8157-8160
9. Kim YM, Kim EC, Kim Y (2011) The human lysyl oxidase-like 2 protein functions as an amine oxidase toward collagen and elastin. Mol Biol Rep 38:145-149
10. Fong SF, Dietzsch E, Fong KS, Hollosi P, Asuncion L, He Q, Parker MI, Csiszar K (2007) Lysyl oxidase-like 2 expression is increased in colon and esophageal tumors and associated with less differentiated colon tumors. Genes Chromosom Cancer 46:644-655
11. Offenberg H, Brunner N, Mansilla F, Orntoft Torben F, Birkenkamp-Demtroder K (2008) TIMP-1 expression in human colorectal cancer is associated with TGF-B1, LOXL2, INHBA1, TNF-AIP6 and TIMP-2 transcript profiles. Mol Oncol 2:233-240
12. Peng L, Ran YL, Hu H, Yu L, Liu Q, Zhou Z, Sun YM, Sun LC, Pan J, Sun LX, Zhao P, Yang ZH (2009) Secreted LOXL2 is a novel therapeutic target that promotes gastric cancer metastasis via the Src/FAK pathway. Carcinogenesis 30:1660-1669
13. Ruckert F, Joensson P, Saeger HD, Grutzmann R, Pilarsky C (2010) Functional analysis of LOXL2 in pancreatic carcinoma. Int J Colorectal Dis 25:303-311
14. Akiri G, Sabo E, Dafni H, Vadasz Z, Kartvelishvily Y, Gan N, Kessler O, Cohen T, Resnick M, Neeman M, Neufeld G (2003) Lysyl oxidase-related protein-1 promotes tumor fibrosis and tumor progression in vivo. Cancer Res 63:1657-1666
15. Erler JT, Bennewith KL, Nicolau M, Dornhofer N, Kong C, Le QT, Chi JT, Jeffrey SS, Giaccia AJ (2006) Lysyl oxidase is essential for hypoxia-induced metastasis. Nature 440:1222-1226
16. Peinado H, Moreno-Bueno G, Hardisson D, Perez-Gomez E, Santos V, Mendiola M, de Diego JI, Nistal M, Quintanilla M, Portillo F, Cano A (2008) Lysyl oxidase-like 2 as a new poor prognosis marker of squamous cell carcinomas. Cancer Res 68:4541-4550. doi: 10.1158/0008-5472.can-07-6345
17. Barry-Hamilton V, Spangler R, Marshall D, McCauley S, Rodriguez HM, Oyasu M, Mikels A, Vaysberg M, Ghermazien H, Wai C, Garcia CA, Velayo AC, Jorgensen B, Biermann D, Tsai D, Green J, Zaffryar-Eilot S, Holzer A, Ogg S, Thai D, Neufeld G, Van Vlasselaer P, Smith V (2010) Allosteric inhibition of lysyl oxidase-like-2 impedes the development of a pathologic microenvironment. Nat Med 16:1009-1017
18. Barker HE, Chang J, Cox TR, Lang G, Bird D, Nicolau M, Evans HR, Gartland A, Erler JT (2011) LOXL2-mediated matrix remodeling in metastasis and mammary gland involution. Cancer Res 71:1561-1572
19. Barker HE, Cox TR, Erler JT (2012) The rationale for targeting the LOX family in cancer. Nat Rev Cancer 12:540-552
20. Peinado H, Del Carmen Iglesias-de la Cruz M, Olmeda D, Csiszar K, Fong KS, Vega S, Nieto MA, Cano A, Portillo F (2005) A molecular role for lysyl oxidase-like 2 enzyme in snail regulation and tumor progression. EMBO J 24:3446-3458. doi: 10.1038/sj.emboj.7600781
21. Moreno-Bueno G, Salvador F, Martin A, Floristan A, Cuevas EP, Santos V, Montes A, Morales S, Castilla MA, Rojo-Sebastian A, Martinez A, Hardisson D, Csiszar K, Portillo F, Peinado H, Palacios J, Cano A (2011) Lysyl oxidase-like 2 (LOXL2), a new regulator of cell polarity required for metastatic dissemination of basal-like breast carcinomas. EMBO Mol Med 3:528-544. doi: 10.1002/emmm.201100156
22. Hammond ME, Hayes DF, Dowsett M et al (2010) American Society of Clinical Oncology/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer (unabridged version). Arch Pathol Lab Med 134:48-72
23. Wolff AC, Hammond ME, Schwartz JN, Hagerty KL, Allred DC, Cote RJ, Dowsett M, Fitzgibbons PL, Hanna WM, Langer A, McShane LM, Paik S, Pegram MD, Perez EA, Press MF, Rhodes A, Sturgeon C, Taube SE, Tubbs R, Vance GH, van de Vijver M, Wheeler TM, Hayes DF (2007) American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J Clin Oncol 25:118-145
24. Neve RM, Chin K, Fridlyand J, Yeh J, Baehner FL, Fevr T, Clark L, Bayani N, Coppe JP, Tong F, Speed T, Spellman PT, DeVries S, Lapuk A, Wang NJ, Kuo WL, Stilwell JL, Pinkel D, Albertson DG, Waldman FM, McCormick F, Dickson RB, Johnson MD, Lippman M, Ethier S, Gazdar A, Gray JW (2006) A collection of breast cancer cell lines for the study of functionally distinct cancer subtypes. Cancer Cell 10:515-527. doi: 10.1016/j.ccr.2006.10.008
25. Tomaskovic-Crook E, Thompson EW, Thiery JP (2009) Epithelial to mesenchymal transition and breast cancer. Breast Cancer Res 11:213. doi: 10.1186/bcr2416
26. Dent R, Trudeau M, Pritchard KI, Hanna WM, Kahn HK, Sawka CA, Lickley LA, Rawlinson E, Sun P, Narod SA (2007) Triple-negative breast cancer: clinical features and patterns of recurrence. Clin Cancer Res 13:4429-4434
27. Alexieva-Figusch J, Van Putten WL, Blankenstein MA, Blonk-Van Der Wijst J, Klijn JG (1988) The prognostic value and relationships of patient characteristics, estrogen and progestin receptors, and site of relapse in primary breast cancer. Cancer 61:758-768
28. Foulkes WD, Smith IE, Reis-Filho JS (2010) Triple-negative breast cancer. N Engl J Med 363:1938-1948
29. Brekhman V, Neufeld G (2009) A novel asymmetric 3D in vitro assay for the study of tumor cell invasion. BMC Cancer 9:415. doi: 10.1186/1471-2407-9-415
30. Brekhman V, Lugassie J, Zaffryar-Eilot S, Sabo E, Kessler O, Smith V, Golding H, Neufeld G (2011) Receptor activity modifying protein-3 mediates the protumorigenic activity of lysyl oxidase-like protein-2. FASEB J 25:55-65. doi: 10.1096/fj.10-162677
31. Hollosi P, Yakushiji JK, Fong KS, Csiszar K, Fong SF (2009) Lysyl oxidase-like 2 promotes migration in noninvasive breast cancer cells but not in normal breast epithelial cells. Int J Cancer 125:318-327. doi: 10.1002/ijc.24308
32. ClinicalTrioal.gov (2013) First-in-human study of AB0024 to evaluate safety and tolerability in adults with advanced solid tumors. http://www.clinicaltrials.gov/ct2/show/NCT01323933. Accessed Mar 25, 2013